The recall of specific Impella 5.5 devices by Johnson & Johnson's Abiomed is likely to have a negative short-term impact on JNJ's stock price. The reported 179 complaints, three injuries, and no deaths related to the recall indicate a potential issue with the product, which may affect the company's reputation and sales. The recall is directly related to JNJ, making it highly relevant and important for investors.